Home PR Newswire
Friday, March 6, 2026
21.3
C
Bengaluru
Hot topics
If Strategy is Commodity, How Can Organisations Ensure Differentiation?
Strategy and strategic planning are perhaps the most hyped-up...
Covid-19 Impact on Indian Pharma Revenues, Field Force, Doctors – Sunil Attavar, CMD Group Pharma
This is the third and final part of MedicinMan...
First Approach in Pharma
Independence Day Special issue with Vivek Hattangadi tracing the India pharma brand story from before Independence till today.
Rethinking Healthcare Communications for the Indian Context
Indian healthcare is sometimes an enigma: on one hand...
Medical Reps will Remain – What will be their Future Role?
There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it?
“Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s.
The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest.
“Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
Hot topics
American Tariffs and The Rise of the Corporate Superpower
From Nation-States to Corporate Titans: How Innovation is Redrawing...
DiME (Digi MarketEr):-TiME to SHiNE
The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
Indian Pharma – The Emerging Role of Hybrid Sales Model
COVID-19 has accelerated the shift in how pharma was engaging with HCPs, professional organisations and even patients in India from a sales to more of a scientific, unbiased and balanced marketing communications. As one of the business leader from a prominent MNC said, “For the first time we are seeing a certain shift in HCP’s preference for scientific communication for innovators companies. MSLs and scientific operation teams will be playing a key role in the near future.”
Digital Marketing Kick Starter for Pharma Marketers
An interview with Salil Kallianpur - Executive VP at GSK Primary Care on the state of digital in pharma marketing and pointers for digital marketing success.
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
Newsletter
Get important news delivered directly to your inbox and stay connected!